Navigation Links
UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
Date:4/3/2012

BRUSSELS and THOUSAND OAKS, Calif., April 4, 2012 /PRNewswire/ -- UCB (Euronext Brussels: UCB) and Amgen (NASDAQ: AMGN) announced today the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis.

"We look forward to working with UCB on the CDP7851/AMG 785 Phase 3 program," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Despite available osteoporosis therapies, there remains a significant need for additional treatment options that form new bone in women diagnosed with postmenopausal osteoporosis."

"Our sclerostin antibody project with Amgen is one of the most exciting pipeline programs in UCB's portfolio.  Data collected so far indicate the potential for a change of treatment paradigms in postmenopausal osteoporosis," said Prof. Dr. med. Iris Loew-Friedrich, Chief Medical Officer of UCB and Executive Vice-President Global Projects and Development. "We are delighted about the start of the Phase 3 program. The progress made to date encourages and motivates us as we work toward providing a new treatment option for women living with postmenopausal osteoporosis."

The Phase 3 program includes a multicenter, international, randomized, double-blind, placebo-controlled, parallel-group, two-year study in more than 5,000 postmenopausal women with osteoporosis.  The primary endpoint will evaluate the incidence of new vertebral fractures at 12 months. Initial results from the Phase 3 program are expected by the end of 2015.

CDP7851/AMG 785 is a humanized monoclonal antibody that binds to and inhibits sclerostin, a protein secreted by bone cells that inhibits bone formation. By binding to and blocking sclerostin, CDP7851/AMG 785 is designed to increase the amount of bone in the skeleton. With more than 75 million people worldwide suffe
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... has announced the addition of the "Investigation ... report to their offering. Developed by ... of Novolog) is an important drug for the ... aspart, as a fast- acting insulin analog, starts ...
(Date:8/28/2015)... 2015  IP Shakti, LLC, today announced that it has ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... corporate identity signifies our transformation into a company focused on ... for patent claim validity." ... AIA Shield™ platform, the Company commenced a corporate re-branding initiative ...
(Date:8/28/2015)... and PITTSBURGH , ... MYL ) today announced that its shareholders have ... (NYSE: PRGO ; TASE) and the related ... at an extraordinary general meeting of shareholders held ... votes cast at the extraordinary general meeting. In ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... Heska Corporation (NASDAQ: HSKA ), a provider ... , today announced that Robert Grieve, Heska,s Chairman and CEO, ... 2011 at 10:30 a.m. PT / 1:30 p.m. ET.  The ... Hotel in Los Angeles. (Logo: http://photos.prnewswire.com/prnh/20000622/HESKALOGO ) ...
... Md., Sept. 13, 2011 Sodexo, Inc., a leader ... with Healthsense, Inc.  As a part of the agreement, ... existing senior living client communities – expanding Sodexo,s current ... Life for all of the people and communities they ...
Cached Medicine Technology:Heska to Present at LD MICRO Invitational on September 22, 2011 2Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 2Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 3
(Date:8/29/2015)... ... August 30, 2015 , ... Electronic Informed Consent ... – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact about electronic ... , Clinical trial sites can now use audio, video and interactivity ...
(Date:8/29/2015)... ... 29, 2015 , ... Targeted therapies, made possible by a ... patients, according to a newly published report. Surviving Mesothelioma has more on the ... , The authors of the new paper focus on several types of targeted ...
(Date:8/29/2015)... CA (PRWEB) , ... August 29, 2015 , ... ProDrop ... X . Each preset contains 15 seconds of unique footage that users can shrink ... rise, fall, zoom, attract and more. Users can customize color, brightness, scale, speed, range, ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences announced ... Arterosil and Arterosil HP, and that all claims and counterclaims have been irrevocably ... LLC (VHS) in the United States District Court for the Southern District of ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 United Methodists are ... children helping children, a thank you to the many creative and generous ways ... the United Methodist initiative to end malaria deaths. , The Columbus Zoo and ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3
... found those with multiple auras had seizures arising from one ... People with epilepsy who experience multiple types of auras may ... arise from one area of the brain, a U.S. study ... of Neurology , ,included 31 epilepsy patients who experienced ...
... also been linked to Alzheimer,s, researchers note , FRIDAY, ... apolipoprotein E (APOE) e4 gene variant -- associated with ... types of dementia -- are more likely to develop ... gene variant, a U.S. study finds. , Researchers at ...
... The female sex hormone estrogen turns on a gene linked ... , The cancer biology team from UQ,s Diamantina Institute ... help explain the link between breast cancer and high levels ... ability of estrogen to switch this gene on is important ...
... THURSDAY, Aug. 23 (HealthDay News) -- After a heart attack, ... a new study finds. , In fact, recent heart attack ... diabetes compared with the general population and more than 15 ... the report in the Aug. 25 issue of The ...
... The smell fades with time, study shows , THURSDAY, Aug. ... can affect drinking water,s odor but not for long, a ... instead of copper piping, and scientists are trying to evaluate ... In this study, researchers evaluated several types of plastic piping. ...
... from the Sahlgrenska Academy has established that surgery reduces ... follow up has shown that mortality is significantly lower ... do not. , The results are published today ... show for the first time that surgery against obesity ...
Cached Medicine News:Health News:Some Epilepsy Patients Are Good Candidates for Surgery 2Health News:Gene Tied to Post-Op Delirium in Elderly 2Health News:Heart Attack Boosts Diabetes Risk 2Health News:Surgery for severe obesity saves lives 2
... Single Use linear stapler with LACTOMER™ ... Suture™ PREMIUM POLY CS™-57 disposable surgical ... of a temporary opening, such as ... section, or when transecting muscle tissue, ...
... Units With Titanium Staples for ... (Single Use Reloadable Stapler with ... Suture™ PREMIUM MULTIFIRE TA™ stapler ... pediatric and thoracic surgical procedures ...
... Single Use Loading Units for ... (Single Use Reloadable Staplers with ... Suture™ TA™ Reloadable staplers has ... and thoracic surgical procedures for ...
... linear stapler for resection, transection and anastomosis ... MULTIFIRE GIA™ 60 and 80 single use ... 80 single use loading units and the ... use surgical stapler with MULTIFIRE SGIA™ 60 ...
Medicine Products: